受体酪氨酸激酶融合介导的EGFR突变型非小细胞肺癌对EGFR TKI的耐药:多中心分析与文献综述
多中心回顾性分析27例EGFR突变型非小细胞肺癌患者,检测到受体酪氨酸激酶(RTK)融合后接受双靶向EGFR-RTK抑制或融合靶向单药TKI治疗,可评估25例的客观缓解率为24%、疾病控制率为80%,双TKI治疗未观察到新毒性;文献综述汇总59项研究291例患者,以RET融合最常见(50.0%)。
要点
- RTK融合是EGFR TKI旁路耐药机制之一,以ALK融合(42.9%)和RET融合(35.7%)最多见。
- 可评估25例中客观缓解率24%、疾病控制率80%;14例双TKI可评估者分别为21.4%和78.6%。
- 双靶向EGFR-RTK抑制未观察到新毒性,作者认为在EGFR TKI进展后存在可靶向RTK融合的患者中安全有效。
核心结论
- RTK融合的出现是EGFR TKI旁路耐药机制之一。
- 在EGFR TKI进展后存在可靶向RTK融合的患者中,双靶向EGFR-RTK抑制是安全且有效的。
研究设计与样本
- 多中心回顾性分析,检索五家机构2016年3月1日至2023年9月30日组织或血液二代测序检出RTK融合的EGFR突变型非小细胞肺癌患者。
- 共27例患者纳入分析,其中15例在融合检测后接受双TKI治疗,9例接受融合靶向单药TKI治疗。
- 同时进行文献综述,汇总59项研究共291例以RTK融合为主要耐药机制的患者。
主要发现
- 本队列中ALK融合最常见(42.9%),其次为RET融合(35.7%)。
- 中位治疗时间为169天或5.8个月(范围35-1050天)。
- 可评估25例按实体瘤疗效评价标准的客观缓解率为24%,疾病控制率为80%。
- 接受双TKI治疗的可评估14例中,客观缓解率为21.4%,疾病控制率为78.6%。
- 双靶向EGFR-RTK抑制未观察到新毒性。
关键数值与推荐
- 文献综述汇总291例中,RET融合最常见(50.0%),其次为BRAF(13.3%)、ALK(13.3%)、FGFR(10%)、NTRK(5.3%)、EGFR(1.7%)、ROS1(1.3%)、MET(1%)和ERBB(0.7%)。
临床怎么用
- 作者认为,在EGFR TKI进展后存在可靶向RTK融合的患者中,双靶向EGFR-RTK抑制是安全且有效的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Drug resistance remains a major clinical challenge in EGFR-mutant NSCLC tumors owing to pathway reactivation, pathway bypass, and pathway indifference resistance mechanisms to evade tyrosine kinase inhibitor (TKI) suppression. Fusion of receptor tyrosine kinases (RTKs), such as RET, ALK, and FGFR3, has been reported to mediate EGFR TKI resistance. Given the rarity of these fusions and the heterogeneous nature of the condition, no prospective clinical trials evaluated the incidence, safety, and therapeutic benefit of dual EGFR-RTK inhibition. METHODS: We queried clinical databases from multiple institutions to identify patients who had RTK fusions detected on next-generation sequencing testing results from tissue or blood at five institutions: the Second Affiliated Hospital Zhejiang University School of Medicine, Hunan Cancer Hospital, Prince of Wales Hospital Chinese University of Hong Kong, Chao Family Cancer Center, and the University of Texas MD Anderson Cancer Center from March 1, 2016, to September 30, 2023. The data analyzed included objective response rate (ORR) to treatment post RTK fusion detection, duration of treatment, and safety. A comprehensive literature search was conducted to identify patients with RTK fusion as the primary resistance mechanism in EGFR-mutated NSCLC patients. RESULTS: Twenty-seven patients were identified to be eligible in the analysis. ALK fusions were most reported (42.9%), followed by RET fusions (35.7%). Fifteen patients received dual TKI after fusion detection and nine received fusion targeting single TKIs. The median time on treatment was 169 days or 5.8 months (35-1050 d). ORR by the Response Evaluation Criteria in Solid Tumors in the evaluable 25 patients was 24% and the disease control rate was 80%. In 14 evaluable patients who received dual TKI therapy, ORR by the Response Evaluation Criteria in Solid Tumors was 21.4%, and the disease control rate was 78.6%. No new toxicities were observed with dual EGFR-RTK inhibition. In the literature review, after pooling 291 patients from 59 studies, RET fusions were the most common (50.0%), followed by BRAF (13.3%), ALK (13.3%), FGFR (10%), NTRK (5.3%), EGFR (1.7%), ROS1 (1.3%), MET (1%), and ERBB (0.7%). CONCLUSION: The emergence of RTK fusions is one of the mechanisms of bypass resistance of EGFR TKI. Dual inhibition of EGFR-RTK was safe and efficacious in patients with targetable RTK fusion after progression to EGFR TKIs.
引用
- Xia Y, Wang K, Zhao J, et al. Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review. J Thorac Oncol. 2024. PMID: 39622411. doi:10.1016/j.jtho.2024.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。